Lavipharm supported the 5th Conference of “Master Classes in Dementia 2017”
Lavipharm actively participated in the 5th Conference of “Master Classes in Dementia 2017”, hosted by the Hellenic Society of Dementia.
Lavipharm was included in the sponsors of the Conference, which took place on November 3rd to 5th 2017, at the Zappeion, having the opportunity to communicate to the medical community of neurology the benefits of its product portfolio in this therapeutic category.
Nowadays, dementia, in its various forms, has evolved into a common disease that affects nearly 50 million people worldwide, as the increase in life expectancy and aging of the population further contribute to its spreading. According to the National Dementia Action Plan and Alzheimer’s Disease in Greece, patients are numbered approximately 200,000, a figure that is expected to triple up by 2050. The Conference focused on the latest developments in the prevention, diagnosis, and treatment of Alzheimer’s disease and other dementia forms. The scientific program included lectures by distinguished Greek and foreign speakers, Round Tables, Workshops, Researchers Forum and e-posters.
Lavipharm is active in the pharmaceutical field since 1911, with the aim to assist healthcare professionals in their everyday practice by providing them with reliable therapeutic options. Its portfolio includes innovative, safe and effective products that meet the daily health needs of modern consumers.
Lavipharm, with a history of more than a hundred years, is today an integrated Group engaged in the research, development, production, marketing and sales, wholesaling and distribution of pharmaceutical, cosmetic and healthcare products in Greece, with a strong international activity.